

College, Dr. Misra's admission of certain facts in that report, and ORI's own analysis, ORI found that Dr. Misra, a former postdoctoral research associate, Department of Chemistry, Dartmouth College, engaged in scientific misconduct by intentionally altering laboratory notebook data entries for research supported by a grant from the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

Specifically, Dr. Misra altered laboratory notebook data entries in two instances in an effort to conceal prior manipulations of that data without disclosure or explanation to the principal investigator or anyone else. The experiment at issue involved an assay of the chemical activity of a carcinogen, and Dr. Misra's change in the readings of the "control" experiment, in which no carcinogen was present, changed the results.

Dr. Misra has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning April 7, 1997:

(1) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which Dr. Misra's participation is proposed or which uses him in any capacity on PHS supported research must concurrently submit a plan for supervision of his duties. The supervisory plan must be designed to ensure the scientific integrity of Dr. Misra's research contribution. The institution must submit a copy of the supervisory plan to ORI.

No scientific publications were required to be corrected as part of this Agreement.

**FOR FURTHER INFORMATION CONTACT:**  
Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

**Chris B. Pascal,**

*Acting Director, Office of Research Integrity.*  
[FR Doc. 97-9733 Filed 4-15-97; 8:45 am]

BILLING CODE 4160-17-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and the Advisory Commission on Childhood Vaccines (ACCV) Subcommittee on Vaccine Safety: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

*Name:* National Vaccine Advisory Committee (NVAC).

*Times and dates:* 8:45 a.m.-12:15 p.m., May 1, 1997. 8:30 a.m.-1:15 p.m., May 2, 1997.

*Place:* Hubert H. Humphrey Building, Room 703A, 200 Independence Avenue, SW, Washington, DC 20201.

*Status:* Open to the public, limited only by the space available.

*Notice:* In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

*Purpose:* This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

*Matters to be discussed:* Agenda items will include a National Vaccine Program Office (NVPO) update; a discussion on review of the Department of Health and Human Services' Adult Immunization Plan; a discussion on the survey on practices of non-traditional providers; a report of meeting on simian-virus-40—next steps; AIDS vaccine, the progress in vaccine development and organizational approach; the national vaccine plan focusing on priorities; tuberculosis vaccines, barriers and opportunities; the National Institutes of Health (NIH) will discuss their program on tuberculosis and vaccine options; discussion from the Advisory Council on the Elimination of Tuberculosis; improving immunization coverage report from the Sabin Foundation; report from the Subcommittee on Immunization Coverage; report from the Subcommittee on Future Vaccines; report from the Subcommittee on Vaccine Safety; and status of the Work Group on philosophical exemptions.

Agenda items are subject to change as priorities dictate.

*Name:* Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines, Subcommittee on Vaccine Safety.

*Time and date:* 1:15 p.m.-5 p.m., May 1, 1997.

*Place:* Hubert H. Humphrey Building, Room 425A, 200 Independence Avenue, SW, Washington, DC 20201.

*Status:* Open to the public, limited only by the space available.

*Purpose:* This joint NVAC/ACCV subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

*Matters to be discussed:* This subcommittee will discuss the update on the Public Health Service vaccine safety activities; vaccine safety surveillance overview; vaccine safety funding; and agenda items for next meeting.

*Name:* Subcommittee on Immunization Coverage.

*Time and date:* 1:15 p.m.-5 p.m., May 1, 1997.

*Place:* Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

*Status:* Open to the public, limited only by the space available.

*Purpose:* This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

*Matters to be discussed:* This subcommittee will discuss the review of recommendations from the document "Strategies to Sustain Immunization Coverage"; and a discussion and finalization of the recommendations.

*Name:* Subcommittee on Future Vaccines.

*Time and date:* 1:15 p.m.-5 p.m., May 1, 1997.

*Place:* Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

*Matters to be discussed:* This subcommittee will discuss an update on vaccine procurement strategies and case studies in vaccine development.

*Contact person for more information:*  
Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639-7250.

Dated: April 11, 1997.

**John C. Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 97-9902 Filed 4-15-97; 8:45 am]

BILLING CODE 4163-18-P